Diffuse large B-Cell lymphoma

Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring

Ryogo Minamimoto, Luis Fayad, Ranjana Advani, Julie Marie Vose, Homer Macapinlac, Jane L Meza, Jordan Hankins, Felix Mottaghy, Malik Juweid, Andrew Quon

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: To compare the performance characteristics of interim fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (after two cycles of chemotherapy) by using the most prominent standardized interpretive criteria (including International Harmonization Project [IHP] criteria, European Organization for Research and Treatment of Cancer [EORTC] criteria, and PET Response Criteria in Solid Tumors (PERCIST) versus those of interim 18F fluorothymidine (FLT) PET/CT and simple visual interpretation. Materials and Methods: This HIPAA-compliant prospective study was approved by the institutional review boards, and written informed consent was obtained. Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT and FDG PET/CT 18-24 days after two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. For FDG PET/CT interpretation, IHP criteria, EORTC criteria, PERCIST, Deauville criteria, standardized uptake value, total lesion glycolysis, and metabolic tumor volume were used. FLT PET/CT images were interpreted with visual assessment by two reviewers in consensus. The interim (after cycle 2) FDG and FLT PET/CT studies were then compared with the end-of-treatment FDG PET/CT studies to determine which interim examination and/or criteria best predicted the result after six cycles of chemotherapy. Results: From November 2011 to May 2014, there were 60 potential patients for inclusion, of whom 46 patients (24 men [mean age, 60.9 years 6 13.7; range, 28-78 years] and 22 women [mean age, 57.2 years 6 13.4; range, 25-76 years]) fulfilled the criteria. Thirty-four patients had complete response, and 12 had residual disease at the end of treatment. FLT PET/CT had a significantly higher positive predictive value (PPV) (91%) in predicting residual disease than did any FDG PET/CT interpretation method (42%-46%). No difference in negative predictive value (NPV) was found between FLT PET/CT (94%) and FDG PET/CT (82%-95%), regardless of the interpretive criteria used. FLT PET/CT showed statistically higher (P <.001-.008) or similar NPVs than did FDG PET/CT. Conclusion: Early interim FLT PET/CT had a significantly higher PPV than standardized FDG PET/CT-based interpretation for therapeutic response assessment in DLBCL.

Original languageEnglish (US)
Pages (from-to)220-229
Number of pages10
JournalRadiology
Volume280
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Organizations
Research
Neoplasms
Therapeutics
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Health Insurance Portability and Accountability Act
Drug Therapy
Research Ethics Committees
Glycolysis
Etoposide
Tumor Burden
Informed Consent
Positron-Emission Tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Diffuse large B-Cell lymphoma : Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring. / Minamimoto, Ryogo; Fayad, Luis; Advani, Ranjana; Vose, Julie Marie; Macapinlac, Homer; Meza, Jane L; Hankins, Jordan; Mottaghy, Felix; Juweid, Malik; Quon, Andrew.

In: Radiology, Vol. 280, No. 1, 01.07.2016, p. 220-229.

Research output: Contribution to journalArticle

Minamimoto, Ryogo ; Fayad, Luis ; Advani, Ranjana ; Vose, Julie Marie ; Macapinlac, Homer ; Meza, Jane L ; Hankins, Jordan ; Mottaghy, Felix ; Juweid, Malik ; Quon, Andrew. / Diffuse large B-Cell lymphoma : Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring. In: Radiology. 2016 ; Vol. 280, No. 1. pp. 220-229.
@article{d1e11c7baa2f4960b506cf8d4e52eea6,
title = "Diffuse large B-Cell lymphoma: Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring",
abstract = "Purpose: To compare the performance characteristics of interim fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (after two cycles of chemotherapy) by using the most prominent standardized interpretive criteria (including International Harmonization Project [IHP] criteria, European Organization for Research and Treatment of Cancer [EORTC] criteria, and PET Response Criteria in Solid Tumors (PERCIST) versus those of interim 18F fluorothymidine (FLT) PET/CT and simple visual interpretation. Materials and Methods: This HIPAA-compliant prospective study was approved by the institutional review boards, and written informed consent was obtained. Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT and FDG PET/CT 18-24 days after two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. For FDG PET/CT interpretation, IHP criteria, EORTC criteria, PERCIST, Deauville criteria, standardized uptake value, total lesion glycolysis, and metabolic tumor volume were used. FLT PET/CT images were interpreted with visual assessment by two reviewers in consensus. The interim (after cycle 2) FDG and FLT PET/CT studies were then compared with the end-of-treatment FDG PET/CT studies to determine which interim examination and/or criteria best predicted the result after six cycles of chemotherapy. Results: From November 2011 to May 2014, there were 60 potential patients for inclusion, of whom 46 patients (24 men [mean age, 60.9 years 6 13.7; range, 28-78 years] and 22 women [mean age, 57.2 years 6 13.4; range, 25-76 years]) fulfilled the criteria. Thirty-four patients had complete response, and 12 had residual disease at the end of treatment. FLT PET/CT had a significantly higher positive predictive value (PPV) (91{\%}) in predicting residual disease than did any FDG PET/CT interpretation method (42{\%}-46{\%}). No difference in negative predictive value (NPV) was found between FLT PET/CT (94{\%}) and FDG PET/CT (82{\%}-95{\%}), regardless of the interpretive criteria used. FLT PET/CT showed statistically higher (P <.001-.008) or similar NPVs than did FDG PET/CT. Conclusion: Early interim FLT PET/CT had a significantly higher PPV than standardized FDG PET/CT-based interpretation for therapeutic response assessment in DLBCL.",
author = "Ryogo Minamimoto and Luis Fayad and Ranjana Advani and Vose, {Julie Marie} and Homer Macapinlac and Meza, {Jane L} and Jordan Hankins and Felix Mottaghy and Malik Juweid and Andrew Quon",
year = "2016",
month = "7",
day = "1",
doi = "10.1148/radiol.2015150689",
language = "English (US)",
volume = "280",
pages = "220--229",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Diffuse large B-Cell lymphoma

T2 - Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring

AU - Minamimoto, Ryogo

AU - Fayad, Luis

AU - Advani, Ranjana

AU - Vose, Julie Marie

AU - Macapinlac, Homer

AU - Meza, Jane L

AU - Hankins, Jordan

AU - Mottaghy, Felix

AU - Juweid, Malik

AU - Quon, Andrew

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose: To compare the performance characteristics of interim fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (after two cycles of chemotherapy) by using the most prominent standardized interpretive criteria (including International Harmonization Project [IHP] criteria, European Organization for Research and Treatment of Cancer [EORTC] criteria, and PET Response Criteria in Solid Tumors (PERCIST) versus those of interim 18F fluorothymidine (FLT) PET/CT and simple visual interpretation. Materials and Methods: This HIPAA-compliant prospective study was approved by the institutional review boards, and written informed consent was obtained. Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT and FDG PET/CT 18-24 days after two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. For FDG PET/CT interpretation, IHP criteria, EORTC criteria, PERCIST, Deauville criteria, standardized uptake value, total lesion glycolysis, and metabolic tumor volume were used. FLT PET/CT images were interpreted with visual assessment by two reviewers in consensus. The interim (after cycle 2) FDG and FLT PET/CT studies were then compared with the end-of-treatment FDG PET/CT studies to determine which interim examination and/or criteria best predicted the result after six cycles of chemotherapy. Results: From November 2011 to May 2014, there were 60 potential patients for inclusion, of whom 46 patients (24 men [mean age, 60.9 years 6 13.7; range, 28-78 years] and 22 women [mean age, 57.2 years 6 13.4; range, 25-76 years]) fulfilled the criteria. Thirty-four patients had complete response, and 12 had residual disease at the end of treatment. FLT PET/CT had a significantly higher positive predictive value (PPV) (91%) in predicting residual disease than did any FDG PET/CT interpretation method (42%-46%). No difference in negative predictive value (NPV) was found between FLT PET/CT (94%) and FDG PET/CT (82%-95%), regardless of the interpretive criteria used. FLT PET/CT showed statistically higher (P <.001-.008) or similar NPVs than did FDG PET/CT. Conclusion: Early interim FLT PET/CT had a significantly higher PPV than standardized FDG PET/CT-based interpretation for therapeutic response assessment in DLBCL.

AB - Purpose: To compare the performance characteristics of interim fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (after two cycles of chemotherapy) by using the most prominent standardized interpretive criteria (including International Harmonization Project [IHP] criteria, European Organization for Research and Treatment of Cancer [EORTC] criteria, and PET Response Criteria in Solid Tumors (PERCIST) versus those of interim 18F fluorothymidine (FLT) PET/CT and simple visual interpretation. Materials and Methods: This HIPAA-compliant prospective study was approved by the institutional review boards, and written informed consent was obtained. Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT and FDG PET/CT 18-24 days after two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. For FDG PET/CT interpretation, IHP criteria, EORTC criteria, PERCIST, Deauville criteria, standardized uptake value, total lesion glycolysis, and metabolic tumor volume were used. FLT PET/CT images were interpreted with visual assessment by two reviewers in consensus. The interim (after cycle 2) FDG and FLT PET/CT studies were then compared with the end-of-treatment FDG PET/CT studies to determine which interim examination and/or criteria best predicted the result after six cycles of chemotherapy. Results: From November 2011 to May 2014, there were 60 potential patients for inclusion, of whom 46 patients (24 men [mean age, 60.9 years 6 13.7; range, 28-78 years] and 22 women [mean age, 57.2 years 6 13.4; range, 25-76 years]) fulfilled the criteria. Thirty-four patients had complete response, and 12 had residual disease at the end of treatment. FLT PET/CT had a significantly higher positive predictive value (PPV) (91%) in predicting residual disease than did any FDG PET/CT interpretation method (42%-46%). No difference in negative predictive value (NPV) was found between FLT PET/CT (94%) and FDG PET/CT (82%-95%), regardless of the interpretive criteria used. FLT PET/CT showed statistically higher (P <.001-.008) or similar NPVs than did FDG PET/CT. Conclusion: Early interim FLT PET/CT had a significantly higher PPV than standardized FDG PET/CT-based interpretation for therapeutic response assessment in DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=84975317571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975317571&partnerID=8YFLogxK

U2 - 10.1148/radiol.2015150689

DO - 10.1148/radiol.2015150689

M3 - Article

VL - 280

SP - 220

EP - 229

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -